D. Sissoko, C. Laouenan, E. Folkesson, M. 'lebing, A. B. Beavogui et al., Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof of concept trial in Guinea, PLoS Med, vol.13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01327168

T. H. Nguyen, J. Guedj, X. Anglaret, C. Laouénan, V. Madelain et al., Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis, vol.11, issue.2, p.5389, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02309055

P. Chinello, N. Petrosillo, S. Pittalis, G. Biava, G. Ippolito et al., QTc interval prolongation during favipiravir therapy in an Ebola virus-infected patient, PLoS Negl Trop Dis, vol.11, issue.12, 2017.

, Guidance for industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2005.

J. Kang, L. Wang, X. L. Chen, D. J. Triggle, and D. Rampe, Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG, Mol Pharmacol, vol.59, pp.122-126, 2001.

R. L. Woosley, . Heise, and K. A. Romero, Crediblemeds.org, QTdrugs List, Accession Date

J. Kang, X. L. Chen, L. Wang, and D. Rampe, Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG, J Pharmacol Exp Ther, vol.299, pp.290-296, 2001.

T. Lorberbaum, K. J. Sampson, J. B. Chang, V. Iyer, R. L. Woosley et al., Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation, J Am Coll Cardiol, vol.68, pp.1756-1764, 2016.

Y. Kumagai, Y. Murakawa, T. Hasunuma, M. Aso, W. Yuji et al., Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther, vol.53, pp.866-874, 2015.

. Clinicaltrials and . Gov, Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults-NCT02026349 ClinicalTrials

R. Kerber, E. Lorenz, S. Duraffour, D. Sissoko, M. Rudolf et al., Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study, J Infect Dis, vol.220, issue.2, pp.195-202, 2019.

, PREVAIL II Writing Group

P. Multi-national, . Ii-study, . Team, R. T. Davey, L. Dodd et al., A randomized, controlled trial of ZMapp for Ebola virus infection, N Engl J Med, vol.375, issue.15, pp.1448-1456, 2016.

B. Diallo, D. Sissoko, N. J. Loman, H. A. Bah, H. Bah et al., Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days, Clin Infect Dis, vol.63, issue.10, pp.1353-1356, 2016.

S. Mulangu, L. E. Dodd, R. T. Davey, and . Jr, A randomized, controlled trial of Ebola virus disease therapeutics, 2019.

, N Engl J Med, 2019.